GSK (LON:GSK) Price Target Raised to GBX 2,200 at Berenberg Bank

GSK (LON:GSK) had its price target hoisted by stock analysts at Berenberg Bank from GBX 2,000 to GBX 2,200 in a note issued to investors on Tuesday, Digital Look reports. The firm presently has a “hold” rating on the stock. Berenberg Bank’s target price suggests a potential upside of 18.38% from the company’s current price.

A number of other brokerages have also commented on GSK. Royal Bank Of Canada reissued a “sector perform” rating and set a GBX 1,975 price target on shares of GSK in a report on Tuesday, September 8th. Jefferies Financial Group restated a “buy” rating and set a GBX 2,500 price objective on shares of GSK in a report on Wednesday, July 29th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a GBX 2,000 target price on shares of GSK in a report on Wednesday, September 2nd. Two research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, GSK presently has a consensus rating of “Hold” and a consensus price target of GBX 2,064.38.

GSK Stock Performance

GSK stock opened at GBX 1,858.50 on Tuesday. GSK has a 52 week low of GBX 1,455 and a 52 week high of GBX 2,282. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 103.36. The stock has a market cap of £74.47 billion, a P/E ratio of 15.78, a price-to-earnings-growth ratio of 1.24 and a beta of 0.29. The stock has a 50 day moving average of GBX 1,899.20 and a 200-day moving average of GBX 1,964.02.

GSK (LON:GSK) last issued its earnings results on Tuesday, July 28th. The company reported GBX 10.80 EPS for the quarter. GSK had a return on equity of 28.35% and a net margin of 14.52%. On average, analysts expect that GSK will post 175.980975 EPS for the current fiscal year.

Insider Activity

In other GSK news, insider Vishal Sikka bought 1,266 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were bought at an average price of GBX 5,069 per share, for a total transaction of £64,173.54. Also, insider Jeannie Lee purchased 802 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average price of GBX 5,069 per share, for a total transaction of £40,653.38. Over the last ninety days, insiders have bought 3,625 shares of company stock worth $13,494,563. Company insiders own 0.20% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.